Strategic Partnerships Potential to expand through collaborations with large life sciences and contract manufacturing organizations given Mytide's automation and predictive analytics for peptide manufacturing, as demonstrated by past partnerships with Agilent.

Leadership & Growth Recent leadership change to Martina Diekmann as CEO signals a new growth and commercialization focus, presenting an opportunity to engage for strategic advisory, funding conversations, and go-to-market alignment.

Capital & Funding Current financing of around seven plus million dollars indicates readiness for scale and pilot projects; tailor outreach around co-development, grantable work, and milestone-based partnerships with potential investors or pharma sponsors.

Go-to-market Readiness Small team size with a scalable technology platform presents a compelling case for services-led partnerships, such as contract manufacturing or pilot-scale partnerships, leveraging automation and ML for rapid deployment.

Technology Enablement Existing tech stack and cloud-based analytics infrastructure position Mytide for integrations with pharma data ecosystems; propose data-sharing, analytics collaboration, and joint development of predictive models to accelerate peptide discovery.